Skip to Content
Merck
  • Both Hypoxia-Inducible Factor 1 and MAPK Signaling Pathway Attenuate PI3K/AKT via Suppression of Reactive Oxygen Species in Human Pluripotent Stem Cells.

Both Hypoxia-Inducible Factor 1 and MAPK Signaling Pathway Attenuate PI3K/AKT via Suppression of Reactive Oxygen Species in Human Pluripotent Stem Cells.

Frontiers in cell and developmental biology (2021-02-09)
Petr Fojtík, Deborah Beckerová, Katerina Holomková, Martin Šenfluk, Vladimir Rotrekl
ABSTRACT

Mild hypoxia (5% O2) as well as FGFR1-induced activation of phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B (PI3K/AKT) and MAPK signaling pathways markedly support pluripotency in human pluripotent stem cells (hPSCs). This study demonstrates that the pluripotency-promoting PI3K/AKT signaling pathway is surprisingly attenuated in mild hypoxia compared to the 21% O2 environment. Hypoxia is known to be associated with lower levels of reactive oxygen species (ROS), which are recognized as intracellular second messengers capable of upregulating the PI3K/AKT signaling pathway. Our data denote that ROS downregulation results in pluripotency upregulation and PI3K/AKT attenuation in a hypoxia-inducible factor 1 (HIF-1)-dependent manner in hPSCs. Using specific MAPK inhibitors, we show that the MAPK pathway also downregulates ROS and therefore attenuates the PI3K/AKT signaling-this represents a novel interaction between these signaling pathways. This inhibition of ROS initiated by MEK1/2-ERK1/2 may serve as a negative feedback loop from the MAPK pathway toward FGFR1 and PI3K/AKT activation. We further describe the molecular mechanism resulting in PI3K/AKT upregulation in hPSCs-ROS inhibit the PI3K's primary antagonist PTEN and upregulate FGFR1 phosphorylation. These novel regulatory circuits utilizing ROS as second messengers may contribute to the development of enhanced cultivation and differentiation protocols for hPSCs. Since the PI3K/AKT pathway often undergoes an oncogenic transformation, our data could also provide new insights into the regulation of cancer stem cell signaling.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-PCNA antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, ab2
Sigma-Aldrich
Okadaic acid from Prorocentrum concavum, 92-100% (HPLC)
Sigma-Aldrich
Wortmannin, from Penicillium funiculosum, ≥98% (HPLC and TLC)
Sigma-Aldrich
2-Mercaptoethanol, for molecular biology, suitable for electrophoresis, suitable for cell culture, BioReagent, 99% (GC/titration)
Sigma-Aldrich
Paraformaldehyde, powder, 95%
Sigma-Aldrich
Goat Anti-Mouse IgG Antibody, HRP conjugate, Upstate®, from goat
Sigma-Aldrich
Anti-19S regulator non-ATPase subunit S5a/Rpn10 Antibody, clone S5a-18, clone S5a-18, Upstate®, from mouse
Sigma-Aldrich
SHIP2 Inhibitor, AS1938909, The SHIP2 Inhibitor, AS1938909 controls the biological activity of SHIP2. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
Sigma-Aldrich
Cobalt(II) chloride, purum p.a., anhydrous, ≥98.0% (KT)
Roche
cOmplete, Mini Protease Inhibitor Cocktail, Tablets provided in a glass vial
Sigma-Aldrich
MISSION® esiRNA, targeting human HIF1A
Sigma-Aldrich
MISSION® esiRNA, targeting human PTEN
Sigma-Aldrich
PD184352, ≥98% (HPLC)
Sigma-Aldrich
N-Ethylmaleimide, BioUltra, ≥99.0% (HPLC)
Sigma-Aldrich
L-Glutathione reduced, suitable for cell culture, BioReagent, ≥98.0%, powder